<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE OF REVIEW: To summarize the available evidence concerning the occurrence and treatment of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in patients supported with long-term ventricular assist devices (VADs) </plain></SENT>
<SENT sid="1" pm="."><plain>RECENT FINDINGS: Approximately one-third of left ventricular assist device-supported patients experience significant <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, with higher rates in certain patient subsets </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0004308'>Ventricular arrhythmias</z:hpo> are associated with both increased mortality and morbidity in VAD-supported patients </plain></SENT>
<SENT sid="3" pm="."><plain>Mechanical factors, <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> and alterations in cardiac myocyte <z:mp ids='MP_0001532'>physiology</z:mp> because of myocardial unloading are contributors to <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in this population </plain></SENT>
<SENT sid="4" pm="."><plain>In the absence of definitive trials, current evidence supports implanted cardioverter defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>) in long-term VAD patients to mitigate the risks associated with <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Though antiarrhythmic therapies have limited efficacy, amelioration of inflow cannula contact with the endocardium and suction events or ablation of specific anatomic origins of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo>, when present, are also efficacious in VAD-supported hearts </plain></SENT>
<SENT sid="6" pm="."><plain>SUMMARY: As the application of long-term VAD support continues to grow, it will be increasingly important to clarify and target the mechanisms contributing to <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in this population </plain></SENT>
<SENT sid="7" pm="."><plain>Prospective trials assessing the benefits of de-novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> placement, ablative strategies and other prophylactic and therapeutic interventions will be increasingly important to further improve the survival and quality of life among VAD-supported patients </plain></SENT>
</text></document>